Dimension Inx
Develops patented 3D-Painting biomaterials platform and rapid-manufacturing process for creating 3D-printed implants for tissue repair, regeneration, and organ restoration; commercializes FDA-cleared CMFlex™ synthetic bone graft using bioprinting technology.
- CEO / Founder
- Caralynn Nowinski Collens
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $15.4M
- Latest Round
- Series A
- Key Investors
- Prime Movers Lab (Series A lead); KdT Ventures (Seed lead); Alumni Ventures; Satori Capital; Prithvi Ventures; Ravelin Capital; B Capital Group; Incisive Ventures; Negev Capital; Parkway VC; Pioneer Fund; Revolution (Rise of the Rest Seed Fund); Solas BioVentures; Portal Innovation Ventures
Technology & Products
Key Products
CMFlex™ (3D-printed synthetic bone graft, FDA 510(k) cleared, first commercial product); 3D-Painting System (patented high-loading bioactive ingredient platform); BioNidum™ (cell delivery system for tissue engineering); Custom biomaterial solutions for tissue regeneration applications
Technological Advantage
Patented 3D-Painting System enables unprecedented control over material microarchitecture and bioactive loading (vs. conventional molded/sintered bone grafts); scalable manufacturing on Desktop Health 3D-Bioplotter reduces per-unit production cost and lead time from months to days; protected intellectual property in US, Japan, Australia covering the printing system and material compositions.
Differentiation
Value Proposition
Enables rapid manufacturing (vs. conventional 5-7 year surgical implant development cycles) of off-the-shelf, 3D-printed synthetic bone grafts that replicate native bone microarchitecture, reducing surgical lead times and improving patient outcomes through scalable, biofabricated solutions.
How They Differentiate
Only company with FDA 510(k) cleared 3D-printed synthetic bone graft in commercial use; proprietary high-loading biomaterial formulation + 3D-Painting process delivers superior microarchitecture control vs. competitors; vertical integration (R&D + manufacturing) on proven 3D-Bioplotter hardware; clinical surgeon relationships and first-patient surgical validation (2023) establish market leadership in regenerative orthopedics.
Market & Competition
Target Customers
Orthopedic and reconstructive surgeons; medical device OEMs; regenerative medicine companies
Industry Verticals
Orthopedic surgery; Regenerative medicine; Medical devices; Tissue engineering; Biotech/pharma (contract manufacturing)
Competitors
Organovo Holdings (extrusion bioprinting, regenerative medicine); Regemat3D (3D-printed bioscaffolds, tissue engineering); Desktop Metal / Desktop Health (3D bioprinting hardware; CMFlex manufacturing partnership may blur competitive lines); Lattice Biologics (tissue engineering, allograft scaffolds); Tissue Regenix (acellular regenerative medicine products)
Growth & Milestones
Growth Metrics
FDA 510(k) clearance for CMFlex (Q4 2023); first surgical patients treated with CMFlex (2023); $12M Series A closes (Feb 2023) enabling commercialization ramp; headquarters expansion to Fulton Labs (Chicago) to support anticipated team growth; recognized as one of Chicago's top 50 tech companies (2025); 2023 3D Printing Industry Awards – Honorable Mention (Medical, Dental, Health Application category).
Major Milestones
[object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]
Notable Customers
Orthopedic and reconstructive surgeons (CMFlex surgical cases, first patients Q4 2023); Desktop Metal (co-manufacturer and distributor of CMFlex); Medical device OEMs and biotech firms (custom biomaterial solutions via partnership model)